The DOI matches its Crossref record; 128 of the 131 references it cites were found in a registry or an index.
Commonality of the IL-4/IL-13 pathway in atopic diseases
Abstract
INTRODUCTION: Allergy results from an aberrant Type 2 inflammatory response, triggered by a wide range of environmental antigens (allergens) that lead to various immune responses, culminating in the production of immunoglobulin E (IgE). Two key cytokines, interleukin (IL)-4 and IL-13, are critical to the induction and perpetuation of the Type 2 response, and have been implicated in multiple atopic diseases. Area covered: This review summarizes recent milestone developments that have elucidated components of the pathogenesis of atopic diseases such as atopic dermatitis (AD), asthma, and chronic sinusitis with nasal polyposis (CSwNP). Expert commentary: Several therapeutic agents that selectively target potentiators of the Type 2 pathway have shown efficacy in one or more of these atopic diseases, but few agents have proven to be broadly applicable across all three atopic diseases. Dupilumab, a human monoclonal antibody that simultaneously inhibits signaling of IL-4 and IL-13, has demonstrated significant clinical efficacy in AD, asthma, and CSwNP. The fact that these diseases often occur as comorbidities and respond to the same therapy suggests that there is a common underlying pathogenic pathway, and that IL-4 and IL-13 cytokines are central to regulating the pathogenesis of these atopic diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,599
Asher, M. I., Montefort, S., Björkstén, B., Lai, C. K., Strachan, D. P., Weiland, S. K., & Williams, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69283-0 · Cited by 4,223
Interleukin-13: Central Mediator of Allergic Asthma
Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B., Neben, T. Y., Karp, C. L., & Donaldson, D. D. (1998) · Science · doi:10.1126/science.282.5397.2258 · Cited by 2,617
Fokkens, W. J., Lund, V. J., Mullol, J., Bachert, C., Alobid, I., Baroody, F., Cohen, N., Cervin, A., Douglas, R., Gevaert, P., et al. (2012) · Rhinology journal · doi:10.4193/rhino12.000 · Cited by 2,387 · cited 1×
“The nasal/ paranasal sinus inflammation plus the outgrowth of the mucosa originating from the ostiomeatal sinus complex that forms the polyps lead to symptoms of facial pain, pressure, congestion and loss of smell that last more than 12 weeks [119].”
BackgroundIdentification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program
Moore, W. C., Meyers, D. A., Wenzel, S. E., Teague, W. G., Li, H., Li, X., D'Agostino, R., Castro, M., Curran-Everett, D., Fitzpatrick, A. M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0896oc · Cited by 2,129
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · cited 4×
“Phase 3 trials with identical designs (Liberty AD SOLO1 and SOLO2, N = 1,379) [52], replicated the robust disease improve-”
BackgroundInfluentialSelf-citationCluster analysis and clinical asthma phenotypes
Haldar, P., Pavord, I. D., Shaw, D. E., Berry, M. A., Thomas, M., Brightling, C. E., Wardlaw, A. J., & Green, R. H. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200711-1754oc · Cited by 1,987
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., Marshall, R. P., Bradding, P., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,871
Requirement for IL-13 Independently of IL-4 in Experimental Asthma
Grünig, G., Warnock, M., Wakil, A. E., Venkayya, R., Brombacher, F., Rennick, D. M., Sheppard, D., Mohrs, M., Donaldson, D. D., Locksley, R. M., et al. (1998) · Science · doi:10.1126/science.282.5397.2261 · Cited by 1,849
T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma
Woodruff, P. G., Modrek, B., Choy, D. F., Jia, G., Abbas, A. R., Ellwanger, A., Arron, J. R., Koth, L. L., & Fahy, J. V. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0392oc · Cited by 1,803 · cited 1×
“the other half had low-TH2 gene expression similar to healthy controls [110].”
Background
Research works printed but not linked: 16
- Thomsen SF, 2015, Eur Respir J, 2
- Normansell R, 2014, Cochrane Database Syst Rev, 1:Cd003559
- Chauhan BF, 2014, Cochrane Database Syst Rev, Cd003137
- Heil PM, 2010, J Dtsch Dermatol Ges, 8, 990
- Powell C, 2015, Cochrane Database Syst Rev, Cd010834
- Gascan H, 1991, J Immunol (Baltimore, Md: 1950)
- Gauvreau GM, 2010, Am J Respir Crit Care Med
- Walsh GM, 2010, Curr Opin Investig Drugs, 11, 1305
- Groves RW, 2007, J Invest Dermatol, 127, S54
- Wenzel SE, 2010, Inhaled pitrakinra, an IL-4/IL-13 antagonist reduces exacberbations in patients with eosinophilic asthma
- 2015, Ist Quarter Res
- Simpson E, 2016, Effiacy and safety of lebrikizumab in patients with atopic dermatitis: a Phase 2 randomized, controlled trial (TREBLE)
- 2016, Global Strategy for Asthma Management and Prevention (Revised 2016)
- Nicola A, 2016, LAVOLTA I and II: design and baseline characteristics of two phase III, randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of lebrikizumab in adult patients with uncontrolled asthma
- Gevaert P, 2013, J Allergy Clin Immunol, 131, e1
- Pawankar R, 2011, WAO White Book on Allergy World Allergy Organization
Cited by
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Castro, M., Corren, J., Pavord, I. D., Maspero, J., Wenzel, S., Rabe, K. F., Busse, W. W., Ford, L., Sher, L., FitzGerald, J. M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804092 · Cited by 1,986
Self-citationBachert, C., Han, J. K., Desrosiers, M., Hellings, P. W., Amin, N., Lee, S. E., Mullol, J., Greos, L. S., Bosso, J. V., Laidlaw, T. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31881-1 · Cited by 1,563
Self-citationAtopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
Bhatt, S. P., Rabe, K. F., Hanania, N. A., Vogelmeier, C. F., Cole, J., Bafadhel, M., Christenson, S. A., Papi, A., Singh, D., Laws, E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303951 · Cited by 521
Le Floc’h, A., Allinne, J., Nagashima, K., Scott, G., Birchard, D., Asrat, S., Bai, Y., Lim, W. K., Martin, J., Huang, T., et al. (2020) · Allergy · doi:10.1111/all.14151 · Cited by 545
“Curr Allergy Asthma Rep 2013;13(5):415-420.”
Metadata
- Authors
- Gandhi, N. A., Pirozzi, G., & Graham, N. M. H.
- Affiliations
- Regeneron (United States) (US)
- Sanofi (United States) (US)
- Corresponding author
- Gandhi, Namita A.
- Venue
- Expert Review of Clinical Immunology
- Publisher
- Informa UK Limited
- Published
- 2017-03-15
- Volume
- 13
- Issue
- 5
- Pages
- 425-437
- ISSN
- 1744-666X (ISSN-L)
- 1744-8409
- OpenAlex
- W2594033175
- Cited by
- 493
- References
- 131
- Citations by year
- 2026: 39 · 2025: 53 · 2024: 75 · 2023: 72 · 2022: 79 · 2021: 69 · 2020: 40 · 2019: 38 · 2018: 19 · 2017: 9
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Clinical Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Regeneron Pharmaceuticals, Sanofi Pharmaceuticals and Genzyme
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Keywords
- IL-4/IL-13 pathway, type 2 inflammation, atopic diseases, atopic dermatitis, asthma, dupilumab, immunoglobulin E, allergic comorbidities
- MeSH terms
- Allergens, Asthma, Chronic Disease, Dermatitis, Atopic, Humans, Nasal Polyps, Sinusitis, Signal Transduction, Interleukin-4, Th2 Cells, Interleukin-13, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Commonality of the IL-4/IL-13 pathway in atopic diseases. https://app.cochat.ai/papers/10.1080/1744666x.2017.1298443
- The paper
- Gandhi, N. A., Pirozzi, G., & Graham, N. M. H. (2017). Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Review of Clinical Immunology. https://doi.org/10.1080/1744666x.2017.1298443
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.